Compare Recursion Pharmaceuticals Inc (RXRX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Williams-Sonoma, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B), while Williams-Sonoma, Inc. trades at $228.08 (market cap $26.83B). The key difference: Williams-Sonoma, Inc. is far larger — about 14.4× Recursion Pharmaceuticals Inc's market cap, and Williams-Sonoma, Inc. pays a 1.33% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WSM | |
|---|---|---|
Market Cap | $1.86B | $26.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $251.81 |
52-Week Low | $2.84 | $168.64 |
Enterprise Value | $1.38B | $27.33B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Williams-Sonoma (WSM) trades at $227.83, up 0.18% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $2.10 exceeding expectations. Revenue growth of 6.2% in Q2 2026 reflects market share gains in a flat home furnishings industry, supported by a robust net income margin of 14.73% and ROE of 54.96%.
The outlook is positive given raised full-year guidance and analyst consensus price target of $252.62, though near-term risks include tariff pressures on margins and technical resistance near $231. Institutional buying, such as HSBC's 12.1% stake increase in Q2 2026, underscores confidence in continued execution amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
